Avellino

• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k … Recruiting
  2023-510240-20-00 4 2022-10-05 Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Ch … Recruiting
  2024-512382-13-00 5 2022-10-04 Migraine (with or without aura)
• Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting
  2023-510433-29-00 5 2020-09-24 Favorable-intermediate-risk Acute Myeloid Leukemia
• A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm … Ended recruitment
  2024-519087-41-00 5 2025-02-03 Breast cancer is the most common form of cancer among women in North A
• Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma Ended recruitment
  2023-506049-52-00 4 2024-10-28 Follicular lymphoma
• A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Ended recruitment
  2023-503714-77-00 4 2024-10-01 Advanced Non-Small Cell Lung Cancer
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Ended recruitment
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c … Ended recruitment
  2024-511169-12-00 5 2023-03-28 Non-Small Cell Lung Cancer
• Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended recruitment
  2023-507187-39-00 5 2023-03-23 High-Risk Non-muscle-invasive Bladder Cancer
• An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in partici … Ended recruitment
  2023-508740-21-00 4 2023-02-15 Non-Small Cell Lung Cancer
• PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended recruitment
  2023-505057-40-00 4 2022-12-02 Lung Cancer, Non-Small Cell
• Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended recruitment
  2023-509825-38-00 5 2022-12-01 Metastatic Non–Small Cell Lung Cancer
• Genetic vaccine for the treatment of microsatellite unstable solid tumors Ended recruitment
  2024-514723-42-00 9 2022-05-05 Locally advanced unresectable or metastatic, microsatellite instabilit
• Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients sufferi … Ended recruitment
  2023-510432-36-00 4 2022-03-01 Acute Myeloid Leukemia with NPM1 mutation
• Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia Ended recruitment
  2023-509441-13-00 4 2022-01-31 Warm autoimmune hemolytic anemia
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph … Ended recruitment
  2024-511636-27-00 5 2021-12-01 Follicular Lymphoma
• A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA … Ended recruitment
  2023-506241-30-00 5 2021-11-30 Advanced Colorectal Cancer with KRAS G12C Mutation
• Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria Ended recruitment
  2023-509843-28-00 5 2021-11-10 Paroxysmal Nocturnal Hemoglobinuria (PNH)
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and … Ended recruitment
  2023-508968-30-00 5 2021-09-08 Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel … Ended recruitment
  2024-511637-35-00 5 2021-03-23 Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
• Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC … Ended recruitment
  2023-507475-21-00 10 2021-01-18 Lung Cancer, Non-Small Cell

Showing 25–48 of 65 trials